4.4 Article

Inflammatory breast cancer outcomes by breast cancer subtype: a population-based study

Journal

FUTURE ONCOLOGY
Volume 15, Issue 5, Pages 507-516

Publisher

FUTURE MEDICINE LTD
DOI: 10.2217/fon-2018-0677

Keywords

inflammatory breast cancer; prognosis; SEER; subtype; survival; treatment

Categories

Funding

  1. Natural Science Foundation of China [81872459, 81803050]
  2. Social Science and Technology Development Major Project of Dongguan [2018507150241630]
  3. Natural Science Foundation of Guangdong Province [2018A030313666]
  4. Science and Technology Planning Projects of Xiamen Science and Technology Bureau [3502Z20174070]

Ask authors/readers for more resources

Aim: To assess the outcomes of breast cancer subtype in inflammatory breast cancer (IBC). Methods: We retrospectively assessed IBC patients from the SEER program. Results: We identified 626 patients, including 230 (36.7%),100 (17.6%), 113 (18.1%), and 173 (27.6%) patients with HoR+/HER2-, HoR+/HER2+, HoR-/HER2+, and HoR-/HER2- subtype disease, respectively. Multivariate analysis demonstrated that, using HoR+/HER2- subtype as reference, patients with HoR+/HER2+ subtype had better breast cancer-specific survival (BCSS) and overall survival (OS), and patients with HoR-/HER2- subtype had worse BCSS and OS, while BCSS and OS were comparable for HoR-/HER2+ subtype. Similar trends were observed in patients who received surgery, radiotherapy, chemotherapy or trimodality therapy. Conclusion: Breast cancer subtype is clinically useful for predicting survival outcome in IBC. The HoR+/HER2- subtype shows poorer survival outcome than HoR+/HER2+ subtype.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available